Log in to search using one of your social media accounts:

 

FDA Okays Pasireotide (Signifor LAR) for AcromegalyFDA Okays Pasireotide (Signifor LAR) for Acromegaly

The long-acting somatostatin analog pasireotide has been approved for the additional indication of treatment of acromegaly in the US, for patients who don't respond well to surgery or first-line agents. FDA Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Related Links:

Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
ConclusionsThe results from these long-term placebo-controlled studies confirm the established safety profile of long-acting OCT, in particular low risk of cardiac, hepatic and renal toxicity in a high-risk population.
Source: Endocrine - Category: Endocrinology Source Type: research
Conclusion Regarding operated cases of GH-producing pituitary adenoma, acromegaly clinical manifestations tended to be milder at diagnosis in later years of the decade, and acromegaly was diagnosed at lower IGF-1 levels and in smaller lesions. Further study is mandatory for the generalization of this trend.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
ConclusionsPEGV effectiveness improves when up titration is appropriate. Higher PEGV doses at start and a more rapid up-titration are necessary in patients with obesity and/or IGF-1  >  2.7 × ULN.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
ConclusionsIn experienced hands, transsphenoidal microsurgery for PAs achieves remission in most patients with a low complication rate. Pituitary function is preserved in most cases and can recover in more than one-third of patients with preoperative hypopituitarism.
Source: Endocrine - Category: Endocrinology Source Type: research
To evaluate the burden of diabetes mellitus (DM) in adult patients with acromegaly treated with second-line pharmacotherapy, from the perspective of the Spanish National Health System (NHS).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Conclusions FGF-21 levels were similar in patients with acromegaly compared to controls. However, our results indicate that FGF-21 may have a potential role in the development of acromegaly complications. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Experimental and Clinical Endocrinology and Diabetes - Category: Endocrinology Authors: Tags: Article Source Type: research
Insulin resistance and the development of diabetes mellitus is a common complication of acromegaly. Prevalence of type 2 diabetes in acromegaly varies from 19 to 56% depending on the case series [1]. In acromegaly, high levels of growth hormone and subsequent stimulation of insulin-like growth factor 1 synthesis contribute to peripheral insulin resistance and the development of diabetes [2]. Although absolute insulin levels may be normal or high, the presence of severe insulin resistance may predispose to diabetic ketoacidosis.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
CONCLUSIONS: In this article, we summarize the pathophysiology, clinical aspects and the new diagnostic tools to better understand bone impairment in acromegaly. PMID: 28880058 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
ConclusionThe validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly.
Source: Pituitary - Category: Endocrinology Source Type: research
More News: Acromegaly | Diabetes | Endocrinology